• Ascentage Pharma corrected a date error in its June 29, 2026 equity-awards announcement covering RSUs and options.
• The annual general meeting date tied to the scheme mandate limit was May 19, 2025, not May 20, 2026.
• All other disclosure in the earlier announcement remains unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-077607), on July 13, 2026, and is solely responsible for the information contained therein.